Related Experiment Video
Updated: May 10, 2026
Isolation of Cortical Microglia with Preserved Immunophenotype and Functionality From Murine Neonates
Published on: January 30, 2014
Microglial ApoD-induced NLRC4 inflammasome activation promotes Alzheimer's disease progression
Yaliang Yu1, Jianzhou Lv1, Dan Ma1
1Department of Neurology, The Second Affiliated Hospital of Henan University of Science and Technology, Luoyang, P. R. China.
Background:
Alzheimer's disease (AD) is a progressive neurodegenerative disease with no effective therapies. It is well known that chronic neuroinflammation plays a critical role in the onset and progression of AD. Well-balanced neuronal-microglial interactions are essential for brain functions. However, determining the role of microglia-the primary immune cells in the brain-in neuroinflammation in AD and the associated molecular basis has been challenging.
Methods:
Inflammatory factors in the sera of AD patients were detected and their association with microglia activation was analyzed. The mechanism for microglial inflammation was investigated. IL6 and TNF-α were found to be significantly increased in the AD stage.
Results:
Our analysis revealed that microglia were extensively activated in AD cerebra, releasing sufficient amounts of cytokines to impair the neural stem cells (NSCs) function. Moreover, the ApoD-induced NLRC4 inflammasome was activated in microglia, which gave rise to the proinflammatory phenotype. Targeting the microglial ApoD promoted NSC self-renewal and inhibited neuron apoptosis. These findings demonstrate the critical role of ApoD in microglial inflammasome activation, and for the first time reveal that microglia-induced inflammation suppresses neuronal proliferation.
Conclusion:
Our studies establish the cellular basis for microglia activation in AD progression and shed light on cellular interactions important for AD treatment.
Insights
Microglia activation in Alzheimer's disease (AD) drives neuroinflammation. Targeting ApoD in microglia promotes neural stem cell renewal and reduces neuron death, offering a potential therapeutic avenue for AD.
Area of Science:
- Neuroscience
- Immunology
- Cell Biology
Background:
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder with significant neuroinflammation.
- Microglia, the brain's immune cells, play a key role in AD pathogenesis, but their precise function remains unclear.
- Proper neuronal-microglial communication is vital for brain health.
Purpose of the Study:
- To investigate the role of microglia in AD-associated neuroinflammation.
- To identify molecular mechanisms underlying microglial activation in AD.
- To explore therapeutic targets for AD based on microglial function.
Main Methods:
- Analysis of inflammatory factors in Alzheimer's disease (AD) patient sera.
- Assessment of microglia activation and its association with inflammatory markers.
- Investigation of the molecular pathways driving microglial inflammation, including the NLRC4 inflammasome.
Main Results:
- Microglia are highly activated in AD brains, releasing cytokines that impair neural stem cell (NSC) function.
- Apolipoprotein D (ApoD) activates the NLRC4 inflammasome in microglia, promoting a pro-inflammatory state.
- Targeting microglial ApoD enhances NSC self-renewal and reduces neuronal apoptosis in AD models.
Conclusions:
- Microglial activation and subsequent inflammation significantly contribute to AD progression.
- The ApoD-NLRC4 inflammasome pathway in microglia is a critical driver of neuroinflammation in AD.
- Modulating microglial ApoD presents a promising therapeutic strategy for AD treatment by protecting neural stem cells and neurons.
More Related Videos
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
06:43A Novel In Vitro Live-imaging Assay of Astrocyte-mediated Phagocytosis Using pH Indicator-conjugated Synaptosomes
Published on: February 5, 2018
Related Concept Videos
01:29Alzheimer Disease l: Introduction
01:23Alzheimer Disease ll: Pathophysiology